All News
Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk
Eric Dein ejdein1 ( View Tweet)
Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
Janet Pope Janetbirdope ( View Tweet)
Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
Janet Pope Janetbirdope ( View Tweet)
Dr Minalyan and colleagues report rates of gout flare following hospital admission of patients prescribed allopurinol. Gout flare 14 times more likely if allopurinol stopped or omitted. @rheumnow #ACR20 Abstr#688 https://t.co/x3eyX1PLFB
Richard Conway RichardPAConway ( View Tweet)
Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk.
#RheumTwitter Abs#0540 #ACR20 @RheumNow
https://t.co/kOSToCljeq
Mrinalini Dey DrMiniDey ( View Tweet)
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
sheila RHEUMarampa ( View Tweet)
Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
David Liew drdavidliew ( View Tweet)
Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed
Session Date Monday, November 9
Presentation Time: 12:15 PM - 12:30 PM ET
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
Lots of JAK safety studies in #ACR20. Abst#0237 pooled 5 RCTs on UPA. Good safety numbers and low VTE rates, but watch out for herpes zoster trend, elevated in UPA (30>15mg) compared to MTX and ADA. @RheumNow
Eric Dein ejdein1 ( View Tweet)
Dr. L Calabrese excellent review of irAEs and a proposed personalized algorithm for mgmt of irAE #ACR20 @LCalabreseDO @rheumnow
He believes there should be more studies combining TNFi or IL-6 with CPI https://t.co/GbvgXtNJnI
k dao KDAO2011 ( View Tweet)
Dr. Noha Abdel-wahab on timing for grade 3/4 irAE fastest with the skin after exposure to CPI #ACR20 @rheumnow https://t.co/sc5c6Zn3Uq
k dao KDAO2011 ( View Tweet)
#hydroxychloroquine is not a ‘cutie’ drug. E Park et al showed that HCQ does not increase QT interval in RA & SLE patients including if on other meds that may affect QT but known heart disease excluded from study #ACR20 #ACR2020 @RheumNow abstr#432 @CRASCRRheum https://t.co/FGVPknmj5q
Janet Pope Janetbirdope ( View Tweet)
More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1 ( View Tweet)
JAKs are no longer new, Winthrop et al presents 8.4 year BARI data in Abst#0202 at #ACR20. VTE risk stable over time, again shows reason to vaccinate patients for zoster before starting. @RheumNow https://t.co/OSIvHl2f7Y
Eric Dein ejdein1 ( View Tweet)
MTX & liver fibrosis:
71% pts w/low FIB-4i of<1.45
No correlation bet FIB-4 values & cumulative MTX dose
Cumulative MTX dose not sig. ⬆ in pts with FIB-4i >1.45 @RheumNow #ACR20 Abstr#0205 https://t.co/RmyAz9M5fw
sheila RHEUMarampa ( View Tweet)
DVT/PE has been the sticking point for baricitinib in RA.
DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either.
Every drug has pros/cons; it's how we manage risk that counts...
#ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
David Liew drdavidliew ( View Tweet)
Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased trigs and BMI associated NAFLD @rheumnow #ACR20 Abstr#0181 https://t.co/WLPuf6Ga1D
Richard Conway RichardPAConway ( View Tweet)
Dr. Izuka talks about drug rxn with TMP-STX in SLE, particularly in anti-Sm at #ACR20 press conference. @HopkinsRheum avoids Bactrim in SLE due to flares. Whats your practice for PJP PPx in SLE? @RheumNow
Eric Dein ejdein1 ( View Tweet)
What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @RheumNow #ACR2020 @CRASCRRheum
Janet Pope Janetbirdope ( View Tweet)
